Get the Stockscreener App
5.17
0.58%
0.03
After Hours:
5.15
-0.02
-0.39%
Atyr Pharma Inc stock is traded at $5.17, with a volume of 2.45M.
It is up +0.58% in the last 24 hours and down -11.32% over the past month.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
See More
Previous Close:
$5.14
Open:
$5.15
24h Volume:
2.45M
Relative Volume:
0.62
Market Cap:
$506.59M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+5.08%
1M Performance:
-11.32%
6M Performance:
+33.59%
1Y Performance:
+176.47%
1-Day Range:
$5.12
$5.3516
1-Week Range:
$4.82
$5.52
52-Week Range:
$1.67
$7.2904
Atyr Pharma Inc Stock (ATYR) Company Profile
Name
Atyr Pharma Inc
Sector
Industry
Phone
(858) 731-8389
Address
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Compare ATYR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
5.17 | 503.65M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-25 | Initiated | Leerink Partners | Outperform |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-04-24 | Initiated | Wells Fargo | Overweight |
| Sep-05-24 | Initiated | Jefferies | Buy |
| Jul-05-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-12-21 | Initiated | RBC Capital Mkts | Outperform |
| Sep-21-21 | Initiated | Piper Sandler | Overweight |
| May-10-21 | Initiated | Laidlaw | Buy |
| Aug-17-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-04-20 | Initiated | ROTH Capital | Buy |
| Mar-02-20 | Initiated | Oppenheimer | Outperform |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-07-17 | Initiated | Piper Jaffray | Overweight |
| Dec-13-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-16-15 | Initiated | Citigroup | Neutral |
| Jun-01-15 | Initiated | Citigroup | Buy |
| Jun-01-15 | Initiated | JP Morgan | Overweight |
View All
Atyr Pharma Inc Stock (ATYR) Latest News
Top chart patterns to watch in aTyr Pharma Inc.Trend Reversal & Entry and Exit Point Strategies - Newser
How to track smart money flows in aTyr Pharma Inc.Weekly Risk Report & Stepwise Entry/Exit Trade Alerts - Newser
Does aTyr Pharma Inc. qualify in momentum factor screeningFed Meeting & Proven Capital Preservation Methods - Newser
aTyr Pharma: Why My Playbook Says 'Wait, Then Act' (NASDAQ:ATYR) - Seeking Alpha
2 Small-Cap Biotech Stocks Well Positioned for a Breakout - Nasdaq
Technical analysis overview for aTyr Pharma Inc. stockMarket Performance Report & Stock Portfolio Risk Control - Newser
Live market analysis of aTyr Pharma Inc.2025 Earnings Impact & Step-by-Step Trade Execution Guides - Newser
aTyr Pharma Inc.’s volatility index tracking explainedMarket Sentiment Summary & Stepwise Entry/Exit Trade Alerts - Newser
Risk adjusted return profile for aTyr Pharma Inc. analyzedSell Signal & Safe Entry Trade Reports - Newser
How to escape a deep drawdown in aTyr Pharma Inc.Market Performance Summary & Real-Time Stock Entry Alerts - Newser
What data driven models say about aTyr Pharma Inc.’s futureMarket Growth Report & Daily Volume Surge Signals - Newser
Regression analysis insights on aTyr Pharma Inc. performanceJuly 2025 Sentiment & Weekly Market Pulse Alerts - Newser
Analyzing drawdowns of aTyr Pharma Inc. with statistical toolsMarket Growth Review & Capital Protection Trade Alerts - Newser
Developing predictive dashboards with aTyr Pharma Inc. dataJuly 2025 Market Mood & Fast Exit Strategy with Risk Control - Newser
Heatmap analysis for aTyr Pharma Inc. and competitorsLong Setup & Free Growth Oriented Trading Recommendations - Newser
Using fundamentals and technicals on aTyr Pharma Inc.Market Movement Recap & Fast Entry and Exit Trade Plans - Newser
Is aTyr Pharma Inc. stock bottoming outQuarterly Trade Summary & Weekly Chart Analysis and Trade Guides - Newser
What institutional flow reveals about aTyr Pharma Inc.July 2025 Big Picture & Smart Swing Trading Alerts - Newser
How to use a screener to detect aTyr Pharma Inc. breakouts2025 Year in Review & Expert-Curated Trade Recommendations - Newser
Applying Elliott Wave Theory to aTyr Pharma Inc.July 2025 Spike Watch & Stepwise Trade Signal Implementation - Newser
Published on: 2025-08-24 08:03:39 - Newser
Is aTyr Pharma Inc. exposed to political riskInsider Selling & High Yield Equity Trading Tips - theviewers.co.kr
Portfolio Recap: Is aTyr Pharma Inc. stock heavily shortedJuly 2025 PostEarnings & Daily Profit Maximizing Trade Tips - theviewers.co.kr
why atyr pharma inc. stock attracts strong analyst attention2025 Trading Recap & Consistent Growth Stock Picks - Newser
Traders Consider Averaging Down in aTyr Pharma Inc.Trade Entry Report & AI Powered Buy and Sell Recommendations - beatles.ru
What is aTyr Pharma Inc.’s book value per share2025 Geopolitical Influence & Entry and Exit Point Strategies - theviewers.co.kr
Nvidia To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Jefferies Updates aTyr Pharma (ATYR) Rating with Increased Price Target | ATYR Stock News - GuruFocus
aTyr Pharma Inc. At Critical Juncture — Bounce or BreakdownJuly 2025 Momentum & Community Verified Swing Trade Signals - beatles.ru
ATyr Pharma Rated as Overweight at Cantor Fitzgerald on Efzofitimod Expectations - MSN
Is it too late to sell aTyr Pharma Inc.Risk Management & Real-Time Buy Signal Alerts - Newser
Moving Average Crossover Confirms Uptrend in aTyr Pharma Inc.2025 Bull vs Bear & Stepwise Trade Execution Plans - beatles.ru
What makes aTyr Pharma Inc. stock price move sharplyNew Guidance & High Return Stock Watch Alerts - beatles.ru
High Growth US Tech Stocks To Watch In August 2025 - Yahoo Finance
RSI Crosses Above 30 for aTyr Pharma Inc. — Reversal in SightTrade Analysis Summary & Daily Stock Trend Reports - beatles.ru
aTyr Pharma: Estimating Their Phase 3 Lung Disease Trial Outcome (NASDAQ:ATYR) - Seeking Alpha
Atyr Pharma Inc Stock (ATYR) Financials Data
There is no financial data for Atyr Pharma Inc (ATYR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.98%
8.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):